Amneal Pharmaceuticals, Inc. (AMRX): Price and Financial Metrics


Amneal Pharmaceuticals, Inc. (AMRX)

Today's Latest Price: $4.95 USD

0.28 (6.00%)

Updated Jun 5 4:10pm

Add AMRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

AMRX Stock Summary

  • Amneal Pharmaceuticals Inc's stock had its IPO on March 27, 2018, making it an older stock than merely 5.75% of US equities in our set.
  • AMRX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 96.27% of US stocks.
  • Over the past twelve months, AMRX has reported earnings growth of 187.41%, putting it ahead of 93.3% of US stocks in our set.
  • Stocks that are quantitatively similar to AMRX, based on their financial statements, market capitalization, and price volatility, are ALSN, ST, ITGR, NEXA, and KGC.
  • AMRX's SEC filings can be seen here. And to visit Amneal Pharmaceuticals Inc's official web site, go to www.amneal.com.
AMRX Daily Price Range
AMRX 52-Week Price Range

AMRX Stock Price Chart More Charts


AMRX Price/Volume Stats

Current price $4.95 52-week high $8.01
Prev. close $4.67 52-week low $2.27
Day low $4.70 Volume 2,150,354
Day high $5.00 Avg. volume 1,892,307
50-day MA $3.81 Dividend yield N/A
200-day MA $3.73 Market Cap 1.48B

Amneal Pharmaceuticals, Inc. (AMRX) Company Bio


Amneal Pharmaceuticals (formerly Impax Laboratories) develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The company was founded in 1993 and is based in Hayward, California.

AMRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$4.95$31.02548%

We started the process of determining a valid price forecast for Amneal Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Amneal Pharmaceuticals Inc ranked in the 82th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 550.83% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for AMRX, they are:

  • 18% of the company's capital comes from equity, which is greater than just 7.14% of stocks in our cash flow based forecasting set.
  • Amneal Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 53 -- greater than 94.71% of US stocks with positive free cash flow.
  • Relative to other stocks in its sector (Healthcare), Amneal Pharmaceuticals Inc has a reliance on debt greater than 96.47% of them.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%535%
1%541%
2%548%
3%554%
4%560%
5%567%

Want more companies with a valuation profile/forecast similar to that of Amneal Pharmaceuticals Inc? See CRHM, RHE, CCEL, ANIP, and HZNP.


AMRX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

AMRX Latest Social Stream


Loading social stream, please wait...

View Full AMRX Social Stream

Latest AMRX News From Around the Web

Below are the latest news stories about Amneal Pharmaceuticals Inc that investors may wish to consider to help them evaluate AMRX as an investment opportunity.

AMRX or COLL: Which Is the Better Value Stock Right Now?

AMRX vs. COLL: Which Stock Is the Better Value Option?

Yahoo | June 3, 2020

New Strong Buy Stocks For May 26th

New Strong Buy Stocks For May 26th

Yahoo | May 26, 2020

The Independent Director of Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Jeffrey George, Just Bought A Few More Shares

Even if it's not a huge purchase, we think it was good to see that Jeffrey George, the Independent Director of Amneal...

Yahoo | May 17, 2020

Amneal (AMRX) Moves to Buy: Rationale Behind the Upgrade

Amneal (AMRX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | May 15, 2020

Amneal's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Amneal Pharmaceuticals.

Yahoo | May 15, 2020

Read More 'AMRX' Stories Here

AMRX Price Returns

1-mo 39.44%
3-mo 43.06%
6-mo 39.04%
1-year -35.29%
3-year -68.67%
5-year -89.75%
YTD 2.70%
2019 -64.38%
2018 -18.74%
2017 25.66%
2016 -69.01%
2015 34.97%

Continue Researching AMRX

Here are a few links from around the web to help you further your research on Amneal Pharmaceuticals Inc's stock as an investment opportunity:

Amneal Pharmaceuticals Inc (AMRX) Stock Price | Nasdaq
Amneal Pharmaceuticals Inc (AMRX) Stock Quote, History and News - Yahoo Finance
Amneal Pharmaceuticals Inc (AMRX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9364 seconds.